NCT05169801

To Compare the Efficacy and Safety of BP102 vs. Avastin® in Combination With Paclitaxel/Carboplatin in First-line Treatment of Advanced or Relapsed NSCLC

To Compare the Efficacy and Safety of BP102 in Combination With Paclitaxel/Carboplatin and Avastin® in Combination With Paclitaxel/Carboplatin in First-line Treatment of Advanced or Relapsed NSCLC - a Randomized, Double-blind, Positive Parallel Control, Multicentre Phase III Clinical Trial

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 520 (actual)
• Sponsor: Jiangsu HengRui Medicine Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a randomized, double-blind, positive parallel control, multicentre Phase III clinical trial, a clinical trial of biosimilar drugs, so the type of comparison is equivalence test.

Conditions

• Non-small Cell Lung Cancer(NSCLC)

Interventions

Type	Name	Description
DRUG	BP102, paclitaxel, carboplatin	BP102, paclitaxel, carboplatin
DRUG	Avastin®, paclitaxel, carboplatin	Avastin®, paclitaxel, carboplatin

Timeline

• Start date: 2018-01-25
• Primary completion: 2019-10-21
• Completion: 2021-06-17
• First posted: 2021-12-27
• Last updated: 2021-12-27

Locations

1 site across 1 country: China